O'Rourke Brian, Yang Chia-Ping Huang, Sharp David, Horwitz Susan Band
a Department of Physiology and Biophysics ; Albert Einstein College of Medicine ; Bronx , NY USA.
Cell Cycle. 2014;13(20):3218-21. doi: 10.4161/15384101.2014.950143.
Abstract Eribulin mesylate is a synthetic analog of halichondrin B known to bind tubulin and microtubules, specifically at their protein rich plus-ends, thereby dampening microtubule (MT) dynamics, arresting cells in mitosis, and inducing apoptosis. The proteins which bind to the MT plus-end are known as microtubule plus-end tracking proteins (+TIPs) and have been shown to promote MT growth and stabilization. Eribulin's plus-end binding suggests it may compete for binding sites with known +TIP proteins such as End-binding 1 (EB1). To better understand the impact of eribulin plus-end binding in regard to the proteins which normally bind there, cells expressing GFP-EB1 were treated with various concentrations of eribulin. In a concentration dependent manner, GFP-EB1 became dissociated from the MT plus-ends following drug addition. Similar results were found with immuno-stained fixed cells. Cells treated with low concentrations of eribulin also showed decreased ability to migrate, suggesting the decrease in MT dynamics may have a downstream effect. Extended exposure of eribulin to cells leads to total depolymerization of the MT array. Taken together, these data show eribulin effectively disrupts EB1 +TIP complex formation, providing mechanistic insights into the impact of eribulin on MT dynamics.
Cell Cycle. 2014
Oncotarget. 2015-12-8
Proc Natl Acad Sci U S A. 2009-1-13
BMC Plant Biol. 2017-2-2
Eur J Cell Biol. 2016-8-31
Int J Mol Sci. 2019-5-9
Cell Mol Life Sci. 2017-7
Womens Health (Lond). 2013-11
Mol Cancer Ther. 2008-7
Nat Cell Biol. 2008-4
Nat Rev Mol Cell Biol. 2008-4
Proc Natl Acad Sci U S A. 1980-3
J Natl Cancer Inst. 1990-7-4